Polymerase Chain Reaction (PCR) remains the gold standard technology due to its high accuracy, scalability, cost-efficacy, and established infrastructure. While newer technologies like Next-Generation Sequencing (NGS) and mass spectrometry are advancing, PCR’s widespread regulatory acceptance and availability make it the primary choice for healthcare providers.
The reagents segment dominates the market. Reagents are considered the backbone of diagnostic workflows, essential for ensuring the accuracy, specificity, and reproducibility of tests across various platforms including PCR and hybridization. The increasing volume of global testing and the development of multiplex assays are key drivers for this segment.
Growth is primarily fueled by increased pandemic readiness, a shift toward precision-driven healthcare, the rising prevalence of antimicrobial resistance, and heavy investments by governments in molecular diagnostic infrastructure. Additionally, the demand for rapid, high-throughput point-of-care (POC) testing is a significant catalyst.
North America currently leads the market due to its advanced healthcare infrastructure, robust R&D pipelines, and the presence of major industry players. However, the Asia-Pacific region is projected to register the highest growth rate through 2035, driven by increased healthcare spending and expanding diagnostic manufacturing hubs in countries like China and India.
The market faces significant hurdles including the high cost of advanced diagnostic instruments, complex reimbursement frameworks, and infrastructure imbalances in low-to-middle-income countries. These factors often limit the penetration of cutting-edge molecular tools in resource-limited settings.
AI and machine learning are being integrated into diagnostic platforms to enhance predictive accuracy, optimize laboratory workflows, and enable faster pathogen identification. AI-based diagnostic workflows allow clinicians to make informed decisions in record time, significantly improving patient outcomes and pandemic surveillance.
While not a direct replacement for PCR, mass spectrometry is a fast-growing niche technology valued for high-throughput pathogen detection. It is particularly effective for discerning detailed microbial profiles in research and reference laboratories, especially during large-scale screening or outbreak situations.
Recent milestones include Roche Diagnostics expanding its cobas-liat system for respiratory and STI detection (2024), Abbott receiving regulatory clearance for a multiplex PCR respiratory assay (2025), and Thermo Fisher Scientific investing $180 million in a Singapore manufacturing hub to bolster the Asia-Pacific supply chain.
Key opportunities include the development of multiplex assays that can detect several pathogens simultaneously, the expansion of portable point-of-care diagnostics for community health settings, and the integration of cloud-enabled platforms for global data-sharing and outbreak early warning systems.
